Central Administration for Pharmaceutical Care

General Administration for Pharmaceutical Vigilance





جمهورية مصر العربية هيئة الدواء المصرية الإدارة المركزية للرعاية الصيدلية الإدارة العامة لليقظة الصيدلية

COVID-19 Vaccine Janssen: Risk for immune thrombocytopenia (ITP) and venous thromboembolism (VTE)

Dear Healthcare Professional,

Janssen, in agreement with the Egyptian Pharmaceutical Vigilance Center (EPVC) would like to inform you of the following:

Summary

Immune thrombocytopenia (ITP):

- Cases of ITP, some with very low platelet levels ($<20,\!000$ per μL), have been reported very rarely, usually within the first four weeks after receiving COVID-19 Vaccine Janssen. This included cases with bleeding and cases with a fatal outcome. Some of these occurred in individuals with a history of ITP.
- If an individual has a history of ITP, the risks of developing low platelet levels should be considered before vaccination, and platelet monitoring is recommended after vaccination.
- Individuals should be alert to signs and symptoms of ITP, such as spontaneous bleeding, bruising or petechiae.
- Individuals diagnosed with thrombocytopenia within 3 weeks after vaccination with COVID-19 Vaccine Janssen should be actively investigated for signs of thrombosis to assess a potential diagnosis of thrombosis with thrombocytopenia syndrome (TTS) that requires specialised clinical management.

Venous thromboembolism (VTE):

- Venous thromboembolism has been observed rarely following vaccination with COVID-19 Vaccine Janssen.
- The risk of VTE should be considered for individuals with increased risk for thromboembolism.
- Healthcare professionals should be alert to the signs and symptoms of VTE. Those vaccinated should be instructed to seek immediate medical attention if they develop symptoms such as shortness of breath, chest pain, leg pain, leg swelling, or persistent abdominal pain following vaccination.
- Individuals who present with thrombosis within 3 weeks of vaccination should be evaluated for thrombocytopenia to assess a potential diagnosis of thrombosis with thrombocytopenia syndrome (TTS) that requires specialised clinical management.

The benefits of vaccination continue to outweigh the risks.

Background on the safety concern

COVID-19 Vaccine Janssen suspension for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older







Tel.: 237484988

Ext.:1470

The Arab Republic of Egypt Egyptian Drug Authority

Central Administration for Pharmaceutical Care

General Administration for Pharmaceutical Vigilance





جمهورية مصر العربية هيئة الدواء المصرية الإدارة المركزية للرعاية الصيدلية الإدارة العامة لليقظة الصيدلية

Immune thrombocytopenia (ITP)

Although there was no imbalance of thrombocytopenia in clinical trials, review of post-marketing cases support ITP being an adverse drug reaction following vaccination with the COVID-19 Vaccine Janssen. Analysis of key cases and literature suggests individuals with a medical history of ITP might be at an increased risk of decreased platelets and symptomatic ITP following vaccination with the Covid-19 vaccine Janssen. If an individual has a history of ITP, the risks of developing low platelet levels should be considered before vaccination, and platelet monitoring is recommended after vaccination.

Healthcare professionals should be alert to the signs and symptoms of thrombocytopenia. Those vaccinated should be instructed to seek prompt medical attention if they experience spontaneous bleeding, skin bruising (petechia) beyond the site of vaccination after a few days.

Individuals diagnosed with thrombocytopenia within 3 weeks after vaccination with COVID-19 Vaccine Janssen should be actively investigated for signs of thrombosis to assess a potential diagnosis of thrombosis with thrombocytopenia syndrome (TTS) that requires specialised clinical management.

Venous thromboembolism (VTE)

Venous thromboembolism has been observed rarely following vaccination with COVID-19 Vaccine Janssen. This should be considered for individuals at increased risk for venous thromboembolism.

During the double-blind period (median follow-up 123 days) of an ongoing phase 3 study (COV3001), venous thromboembolic events were observed in 26/21,894 (0.1%) of individuals who received COVID-19 Vaccine Janssen and 9/21,882 (0.04%) of individuals who received placebo. Of these, venous thromboembolic events were observed within 28 days in 8 individuals who received COVID-19 Vaccine Janssen and in 4 individuals who received placebo. Deep vein thrombosis and pulmonary embolism were mostly observed (21 individuals who received COVID-19 Vaccine Janssen and 8 individuals who received placebo during the entire double-blind phase). The majority of events were reported in individuals with at least one predisposing risk factor for venous thromboembolism.

In another ongoing phase 3 study (COV3009, 15,708 individuals receiving the vaccine and 15,592 placebo), there was no increase in venous thromboembolic events among individuals who received the COVID-19 Vaccine Janssen (median follow-up time 70 days).

Healthcare professionals should be alert to the signs and symptoms of VTE. Those vaccinated should be instructed to seek immediate medical attention if they develop symptoms such as shortness of breath, chest pain, leg pain, leg swelling, or persistent abdominal pain following vaccination. Individuals who present with thrombosis within 3 weeks of vaccination should be evaluated for thrombocytopenia to assess a potential diagnosis of thrombosis with thrombocytopenia syndrome (TTS) that requires specialized clinical management.

OF:CAP.Care.001.01


Issue/Rev no.: 1/0


Issue Date: 30/09/2021

Rev Date:.../.../

Page **2** of 3









The Arab Republic of Egypt **Egyptian Drug Authority**

Central Administration for Pharmaceutical Care

General Administration for Pharmaceutical Vigilance





جمهورية مصر العربية هيئة الدواء المصرية الإدارة المركزية للرعاية الصيدلية الإدارة العامة لليقظة الصيدلية

Call for reporting

Call for reporting

Healthcare professionals should report any suspected adverse reactions associated with the use of COVID-19 Vaccine Janssen

Janssen PV department:

- Janssen scientific office Address: Building 44, North Teseen street, 5th settlement, New Cairo, P.O Box 11835, Cairo, Egypt
- Contact information details are available on the following https://www.janssen.com/sites/www janssen com/files/janssen covid 19 vaccine contact center inf o_by_country.pdf

Egyptian Pharmacovigilance Center:

- Address: 21 Abd El Aziz Al Soud Street, El-Manial, Cairo, Egypt,

And PO Box: 11451

Telephone: (+2)02 25354100, Extension: 1470

Fax: +202 - 23610497

Email: pv.followup@edaegypt.gov.eg

Online reporting: https://primaryreporting.who-umc.org/EG

OR code:



OF:CAP.Care.001.01 Issue/Rev no.: 1/0 Issue Date: 30/09/2021 **Rev Date:.../.../** Page **3** of 3







Tel.: 237484988

Ext.:1470